CLNN
Price
$2.37
Change
-$0.08 (-3.27%)
Updated
May 23 closing price
Capitalization
21.29M
VRNA
Price
$75.06
Change
+$2.37 (+3.26%)
Updated
May 23 closing price
Capitalization
6.39B
67 days until earnings call
Interact to see
Advertisement

CLNN vs VRNA

Header iconCLNN vs VRNA Comparison
Open Charts CLNN vs VRNABanner chart's image
Clene
Price$2.37
Change-$0.08 (-3.27%)
Volume$158.03K
Capitalization21.29M
Verona Pharma
Price$75.06
Change+$2.37 (+3.26%)
Volume$861.55K
Capitalization6.39B
CLNN vs VRNA Comparison Chart
Loading...
CLNN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CLNN vs. VRNA commentary
May 25, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CLNN is a Hold and VRNA is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
May 25, 2025
Stock price -- (CLNN: $2.37 vs. VRNA: $75.06)
Brand notoriety: CLNN and VRNA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CLNN: 227% vs. VRNA: 65%
Market capitalization -- CLNN: $21.29M vs. VRNA: $6.39B
CLNN [@Biotechnology] is valued at $21.29M. VRNA’s [@Biotechnology] market capitalization is $6.39B. The market cap for tickers in the [@Biotechnology] industry ranges from $298.89B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CLNN’s FA Score shows that 0 FA rating(s) are green whileVRNA’s FA Score has 1 green FA rating(s).

  • CLNN’s FA Score: 0 green, 5 red.
  • VRNA’s FA Score: 1 green, 4 red.
According to our system of comparison, VRNA is a better buy in the long-term than CLNN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CLNN’s TA Score shows that 4 TA indicator(s) are bullish while VRNA’s TA Score has 6 bullish TA indicator(s).

  • CLNN’s TA Score: 4 bullish, 4 bearish.
  • VRNA’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, VRNA is a better buy in the short-term than CLNN.

Price Growth

CLNN (@Biotechnology) experienced а -7.78% price change this week, while VRNA (@Biotechnology) price change was +5.26% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.22%. For the same industry, the average monthly price growth was +3.23%, and the average quarterly price growth was -2.73%.

Reported Earning Dates

CLNN is expected to report earnings on Mar 24, 2025.

VRNA is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+1.22% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
VRNA($6.39B) has a higher market cap than CLNN($21.3M). VRNA YTD gains are higher at: 61.628 vs. CLNN (-55.367). CLNN has higher annual earnings (EBITDA): -24.01M vs. VRNA (-121.41M). VRNA has more cash in the bank: 401M vs. CLNN (9.83M). CLNN has less debt than VRNA: CLNN (20.9M) vs VRNA (244M). VRNA has higher revenues than CLNN: VRNA (119M) vs CLNN (350K).
CLNNVRNACLNN / VRNA
Capitalization21.3M6.39B0%
EBITDA-24.01M-121.41M20%
Gain YTD-55.36761.628-90%
P/E RatioN/AN/A-
Revenue350K119M0%
Total Cash9.83M401M2%
Total Debt20.9M244M9%
FUNDAMENTALS RATINGS
CLNN vs VRNA: Fundamental Ratings
CLNN
VRNA
OUTLOOK RATING
1..100
6533
VALUATION
overvalued / fair valued / undervalued
1..100
83
Overvalued
82
Overvalued
PROFIT vs RISK RATING
1..100
1003
SMR RATING
1..100
9995
PRICE GROWTH RATING
1..100
9334
P/E GROWTH RATING
1..100
96100
SEASONALITY SCORE
1..100
31n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

VRNA's Valuation (82) in the Pharmaceuticals Other industry is in the same range as CLNN (83) in the null industry. This means that VRNA’s stock grew similarly to CLNN’s over the last 12 months.

VRNA's Profit vs Risk Rating (3) in the Pharmaceuticals Other industry is significantly better than the same rating for CLNN (100) in the null industry. This means that VRNA’s stock grew significantly faster than CLNN’s over the last 12 months.

VRNA's SMR Rating (95) in the Pharmaceuticals Other industry is in the same range as CLNN (99) in the null industry. This means that VRNA’s stock grew similarly to CLNN’s over the last 12 months.

VRNA's Price Growth Rating (34) in the Pharmaceuticals Other industry is somewhat better than the same rating for CLNN (93) in the null industry. This means that VRNA’s stock grew somewhat faster than CLNN’s over the last 12 months.

CLNN's P/E Growth Rating (96) in the null industry is in the same range as VRNA (100) in the Pharmaceuticals Other industry. This means that CLNN’s stock grew similarly to VRNA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CLNNVRNA
RSI
ODDS (%)
Bullish Trend 3 days ago
90%
Bearish Trend 3 days ago
77%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
76%
Bearish Trend 3 days ago
82%
Momentum
ODDS (%)
Bearish Trend 3 days ago
83%
Bullish Trend 3 days ago
84%
MACD
ODDS (%)
Bearish Trend 3 days ago
85%
Bullish Trend 3 days ago
86%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
86%
Bullish Trend 3 days ago
82%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
86%
Bullish Trend 3 days ago
82%
Advances
ODDS (%)
Bullish Trend 14 days ago
80%
Bullish Trend 6 days ago
79%
Declines
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 4 days ago
83%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
87%
Bearish Trend 3 days ago
80%
Aroon
ODDS (%)
Bearish Trend 3 days ago
88%
Bullish Trend 3 days ago
85%
View a ticker or compare two or three
Interact to see
Advertisement
CLNN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
CMF55.470.13
+0.23%
iShares California Muni Bond ETF
FLHY23.840.04
+0.17%
Franklin High Yield Corporate ETF
SMI44.27N/A
N/A
VanEck HIP Sustainable Muni ETF
VETZ19.53-0.06
-0.31%
Academy Veteran Impact ETF
DUBS31.76-0.17
-0.53%
Aptus Large Cap Enhanced Yield ETF

CLNN and

Correlation & Price change

A.I.dvisor indicates that over the last year, CLNN has been loosely correlated with BMRN. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if CLNN jumps, then BMRN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CLNN
1D Price
Change %
CLNN100%
-3.27%
BMRN - CLNN
34%
Loosely correlated
-1.59%
KZIA - CLNN
33%
Poorly correlated
+2.58%
GOSS - CLNN
30%
Poorly correlated
+3.45%
QNCX - CLNN
29%
Poorly correlated
+7.77%
VRNA - CLNN
28%
Poorly correlated
+3.26%
More

VRNA and

Correlation & Price change

A.I.dvisor indicates that over the last year, VRNA has been loosely correlated with TRDA. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if VRNA jumps, then TRDA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VRNA
1D Price
Change %
VRNA100%
+3.26%
TRDA - VRNA
40%
Loosely correlated
-1.57%
COGT - VRNA
39%
Loosely correlated
-3.21%
ROIV - VRNA
39%
Loosely correlated
-0.64%
CRNX - VRNA
39%
Loosely correlated
-1.16%
ZYME - VRNA
38%
Loosely correlated
+0.52%
More